Tranilast 98.0%(HPLC)
98.0%(HPLC)
Properties
| Vapour pressure | 0.0±1.7 mmHg at 25℃ |
| Assay Purity | >98%(HPLC) |
| Refractive index | 1.648 |
| B pt. | 585.6℃ at 760 mmHg |
| M pt. | 209℃(dec.) |
| Density | 1.299 g/cm3 |
Safety Information
| Hazard Statement(s) | H302 |
| Precautionary Statement | P501-P270-P264-P301 + P312 + P330 |
| Symbol |
|
| Signal word | Warning |
| Storage Temp. | 0-10℃ |
| Packaging | Glass Bottle |
Description
Application
The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.
Purpose
For R&D use onlynot for drug household or other uses.
General Description
Tranilast (INN brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma allergic rhinitis and atopic dermatitis.
Documents
| SDS |
| COA |
| Specification |
| Bulk quote order form |